Effects of PTH(1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial

被引:96
|
作者
Sikjaer, T. [1 ]
Rolighed, L. [2 ]
Hess, A. [3 ]
Fuglsang-Frederiksen, A. [3 ]
Mosekilde, L. [1 ]
Rejnmark, L. [1 ]
机构
[1] Aarhus Univ Hosp, Dept Internal Med & Endocrinol, MEA, Osteoporosis Clin, DK-8000 Aarhus, Denmark
[2] Aarhus Univ Hosp, Dept Surg P, DK-8000 Aarhus, Denmark
[3] Aarhus Univ Hosp, Dept Clin Neurophysiol, DK-8000 Aarhus, Denmark
关键词
Hypoparathyroidism; Muscle function; Quality of life; rhPTH(1-84); PARATHYROID-HORMONE; 1-34; HYPOCALCEMIC MYOPATHY; IDIOPATHIC HYPOPARATHYROIDISM; AMPLITUDE; STRENGTH; BALANCE; GO;
D O I
10.1007/s00198-014-2677-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effects of treatment with 100 mu g parathyroid hormone (PTH) (1-84) or an identical placebo on muscle function and quality of life (QoL) was studied in hypoparathyroid patients. At baseline, we found reduced QoL but no myopathy in the patients. Six months of treatment did not improve QoL, and muscle strength decreased slightly. A reduced quality of life (QoL) and myopathy that may be due to the absence of PTH have been reported in patients with hypoparathyroidism (hypoPT). Sixty-two patients with chronic hypoPT were randomized to 6 months of treatment with either PTH(1-84) 100 mu g/d s.c. or placebo, given as add-on therapy to conventional treatment. Muscle function and postural stability were investigated using a dynamometer chair, a stadiometer platform, the repeated chair stands test, the timed up and go test, and electromyography. QoL was assessed using the 36-item Short Form Health Survey and the WHO-5 Well-Being Index. The mean age of the patients was 52 +/- 11 years, and 85 % were females. At baseline, QoL was significantly reduced in comparison with norm-based scores. Compared with placebo, PTH did not improve QoL or muscle function. Rather, max force production decreased significantly by 30 % at elbow flexion in the PTH group compared with the placebo group. Moreover, there was a nonsignificant trend for muscle strength to decrease in the upper extremities and on knee extension in response to PTH. Treatment did not affect postural stability. Electromyography showed a slight decrease in the duration of motor unit potentials in the PTH group, indicating a tendency toward myopathy, which, however was not symptomatic. Overall, our data do not support an immediate beneficial effect of PTH replacement therapy on muscle function or QoL. A high frequency of hypercalcemia among our patients may have compromised the potential beneficial effects of reversing the state of PTH insufficiency.
引用
收藏
页码:1717 / 1726
页数:10
相关论文
共 50 条
  • [41] The effect of PTH(1-84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial
    Quesada-Gomez, J. M.
    Muschitz, C.
    Gomez-Reino, J.
    Greisen, H.
    Andersen, H. S.
    Dimai, H. P.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2011, 22 (09) : 2529 - 2537
  • [42] Safety and efficacy of PTH(1-84) at 18 and 24 months in women with postmenopausal osteoporosis receiving hormone therapy: Results from the POWER study
    Fogelman, I
    Christiansen, C
    Spector, T
    Fraser, W
    Fordham, J
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S21 - S22
  • [43] Expressive Arts Therapy improves quality of life in multiple sclerosis - results of a randomized controlled trial
    Sterz, C.
    Heimes, S.
    Blessing, T.
    Flachenecker, P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (05) : S47 - S47
  • [44] Serum calcium levels in postmenopausal women with osteoporosis after 1, 6 and 12 months of PTH(1-84) treatment - The latest results from the peak trial
    Diaz-Curiel, M.
    Hosking, D.
    Brandi, M.
    Hyldstrup, L. H.
    Felsenberg, D.
    [J]. BONE, 2009, 44 (02) : S435 - S436
  • [45] The effects of radiation therapy on quality of life of women with breast carcinoma - Results of a randomized trial
    Whelan, TJ
    Levine, M
    Julian, J
    Kirkbride, P
    Skingley, P
    [J]. CANCER, 2000, 88 (10) : 2260 - 2266
  • [46] PTH 1-34 Replacement Therapy has Minimal Effect on Quality of Life in Patients with Hypoparathyroidism
    Gafni, Rachel I.
    Hu, Tiffany
    Guthrie, Lori C.
    Brillante, Beth A.
    Smith, Michaele
    James, Robert
    Collins, Michael T.
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 131 - 131
  • [47] Epilepsy surgery and meaningful improvements in quality of life: Results from a randomized controlled trial
    Fiest, Kirsten M.
    Sajobi, Tolulope T.
    Wiebe, Samuel
    [J]. EPILEPSIA, 2014, 55 (06) : 886 - 892
  • [48] SERUM CALCIUM LEVELS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AFTER 1, 6 AND 12 MONTHS OF PTH(1-84) TREATMENT - THE LATEST RESULTS FROM THE PEAK TRIAL
    Diaz-Curiel, M.
    Hosking, D.
    Brandi, M. L.
    Felsenberg, D.
    Hyldstrup, L.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 71 - 71
  • [49] PTH 1-34 Replacement Therapy Has Minimal Effect on Quality of Life in Patients With Hypoparathyroidism
    Roszko, Kelly L.
    Hu, Tiffany Y.
    Guthrie, Lori C.
    Brillante, Beth A.
    Smith, Michaele
    Collins, Michael T.
    Gafni, Rachel, I
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 (01) : 68 - 77
  • [50] A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for Hypoparathyroidism
    Ing, Steven W.
    Finkelman, Richard D.
    He, Ping
    Khan, Aliya A.
    Mannstadt, Michael
    Rejnmark, Lars
    Song, Ivy
    Takacs, Istvan
    Wu, Yuna
    [J]. JBMR PLUS, 2023, 7 (07)